drugset / Trial / NCT06614621
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
Timeline
- Start
- 2025-02-01
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |